↓ Skip to main content

Biomarkers for immunotherapy in bladder cancer: a moving target

Overview of attention for article published in Journal for Immunotherapy of Cancer, November 2017
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (88th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
21 X users
patent
1 patent

Citations

dimensions_citation
145 Dimensions

Readers on

mendeley
177 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Biomarkers for immunotherapy in bladder cancer: a moving target
Published in
Journal for Immunotherapy of Cancer, November 2017
DOI 10.1186/s40425-017-0299-1
Pubmed ID
Authors

David H. Aggen, Charles G. Drake

Abstract

Treatment options for metastatic urothelial carcinoma (mUC) remained relative unchanged over the last 30 years with combination chemotherapy as the mainstay of treatment. Within the last year the landscape for mUC has seismically shifted following the approval of five therapies targeting the programmed cell death protein (PD-1)/programmed cell death ligand 1 (PD-L1) axis. Notably, the anti-PD-1 antibody pembrolizumab demonstrated improved OS relative to chemotherapy in a randomized phase III study for second line treatment of mUC; this level 1 evidence led to approval from the U.S. Food and Drug Administration (FDA). The PD-1 antibody nivolumab also demonstrated an overall survival benefit, in this case in comparison to historical controls. Similarly, antibodies targeting PD-L1 including atezolizumab, durvalumab, and avelumab have now received accelerated approval from the FDA as second line treatments for mUC, with durable response lasting more than 1 year in some patients. Some of these agents are approved in the first line setting as well - based on single-arm phase II studies atezolizumab and pembrolizumab received accelerated approval for first-line treatment of cisplatin ineligible patients. Despite these multiple approvals, the development of clinically useful biomarkers to determine the optimal treatment for patients remains somewhat elusive. In this review, we examine key clinical trial results with anti-PD1/PD-L1 antibodies and discuss progress towards developing novel biomarkers beyond PD-L1 expression.

X Demographics

X Demographics

The data shown below were collected from the profiles of 21 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 177 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 177 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 27 15%
Researcher 24 14%
Other 11 6%
Student > Bachelor 11 6%
Student > Postgraduate 11 6%
Other 31 18%
Unknown 62 35%
Readers by discipline Count As %
Medicine and Dentistry 38 21%
Biochemistry, Genetics and Molecular Biology 28 16%
Agricultural and Biological Sciences 12 7%
Pharmacology, Toxicology and Pharmaceutical Science 9 5%
Immunology and Microbiology 6 3%
Other 7 4%
Unknown 77 44%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 16. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 27 December 2022.
All research outputs
#2,311,676
of 25,450,869 outputs
Outputs from Journal for Immunotherapy of Cancer
#627
of 3,431 outputs
Outputs of similar age
#49,768
of 446,063 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#14
of 27 outputs
Altmetric has tracked 25,450,869 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 90th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,431 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 446,063 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.